RNA polymerase II subunit IGenealiases: RPB9 · hRPB14.5
Q-omics provides the consensus-scored POLR2I profile across patient tissues and cancer cell-line models. POLR2I expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, POLR2I is differentially expressed in 17, with the highest sampling consensus in KIRC. Additionally, POLR2I protein abundance shows 35,419 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, KIRC, and LSCC as cancer lineages where POLR2I shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POLR2I — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POLR2I survival associations across molecular data types. POLR2I RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POLR2I RNA expression–survival associations across cancer types. High POLR2I expression shows unfavorable associations in ACC, LGG, LIHC, KICH and SKCM, but favorable associations in ESCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for POLR2I RNA expression.
This table summarizes POLR2I tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for POLR2I. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POLR2I shows higher tumor expression in KIRC, COAD, LIHC, LUAD, KIRP and LUSC. The KIRC box plot shows higher POLR2I RNA expression in tumor versus normal tissue (log2 FC = +0.630, t-test p < 0.001).
This table shows molecular features associated with POLR2I in patient tissues and cancer cell lines. In patient samples, POLR2I shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, POLR2I RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
